Literature DB >> 26216557

Methoxetamine-related deaths in the UK: an overview.

Stefania Chiappini1, Hugh Claridge1, John M Corkery1, Christine Goodair1, Barbara Loi1, Fabrizio Schifano1.   

Abstract

OBJECTIVE: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances.
METHODS: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related deaths from Coroners in the UK and Islands (Isle of Man, Jersey, Guernsey) and other data suppliers.
RESULTS: Eight cases, received by 3 September 2013, in which MXE was found at post-mortem and/or directly implicated in the death and/or mentioned in the Coroner's verdict are described. The median age at death was 27 years, with the majority of White ethnicity (6/8) and male (7/8). MXE was used together with other substances in 7/8 cases. MXE was found at post-mortem in all cases, directly implicated in the deaths of four and likely to have had an influence in two.
CONCLUSIONS: More research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE-related poisonings and fatalities.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MXE; NPS; designer drugs; legal high; methoxetamine; novel psychoactive substances

Mesh:

Substances:

Year:  2015        PMID: 26216557     DOI: 10.1002/hup.2422

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

Review 1.  How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances.

Authors:  John Martin Corkery; Fabrizio Schifano; Giovanni Martinotti
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

2.  Fatalities associated with NPS stimulants in the Greater Cologne area.

Authors:  Sabrina Lehmann; Tobias Kieliba; Mario Thevis; Markus A Rothschild; Katja Mercer-Chalmers-Bender
Journal:  Int J Legal Med       Date:  2019-11-18       Impact factor: 2.686

3.  The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission.

Authors:  Anna Mutti; Sonia Aroni; Paola Fadda; Laura Padovani; Laura Mancini; Roberto Collu; Anna Lisa Muntoni; Liana Fattore; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2016-03-28       Impact factor: 4.530

Review 4.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

5.  Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019.

Authors:  John Martin Corkery; Wan-Chu Hung; Hugh Claridge; Christine Goodair; Caroline S Copeland; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2021-06-05       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.